Ballantyne, Christie M.

Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study)

Ballantyne, C. M., Weiss, R., Moccetti, T., Vogt, A., Eber, B., Sosef, F., & Duffield, E. (2007) · The American Journal of Cardiology

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 196

Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial

Bhatt, D. L., Steg, P. G., Brinton, E. A., Jacobson, T. A., Miller, M., Tardif, J., Ketchum, S. B., Doyle, R. T., Murphy, S. A., Soni, P. N., et al. (2017) · Clinical Cardiology

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 183

Sex-Specific Association of Sleep Apnea Severity With Subclinical Myocardial Injury, Ventricular Hypertrophy, and Heart Failure Risk in a Community-Dwelling Cohort: The Atherosclerosis Risk in Communities–Sleep Heart Health Study

Roca, G. Q., Redline, S., Claggett, B., Bello, N., Ballantyne, C. M., Solomon, S. D., & Shah, A. M. (2015) · Circulation

Obstructive Sleep Apnea ResearchSleep and related disorders

Cited by 182

Correlation of serum triglyceride and its reduction by ω-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins

Pownall, H. J., Brauchi, D., Kilinç, C., Osmundsen, K., Pao, Q., Payton-Ross, C., Gotto, A. M., & Ballantyne, C. M. (1999) · Atherosclerosis

Fatty Acid Research and HealthCholesterol and Lipid Metabolism

Cited by 179

Prevalence of coronary heart disease and carotid arterial thickening in patients with the metabolic syndrome (The ARIC Study)

McNeill, A. M., Rosamond, W. D., Girman, C. J., Heiss, G., Golden, S. H., Duncan, B. B., East, H. E., & Ballantyne, C. (2004) · The American Journal of Cardiology

Diabetes, Cardiovascular Risks, and LipoproteinsCardiovascular Health and Disease Prevention

Cited by 177

Efficacy and Safety of a Novel Dual Modulator of Adenosine Triphosphate-Citrate Lyase and Adenosine Monophosphate-Activated Protein Kinase in Patients With Hypercholesterolemia

Ballantyne, C. M., Davidson, M. H., MacDougall, D. E., Bays, H. E., DiCarlo, L. A., Rosenberg, N. L., Margulies, J., & Newton, R. S. (2013) · Journal of the American College of Cardiology

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 175

Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia

Gaudet, D., Pall, D., Watts, G. F., Nicholls, S. J., Rosenson, R. S., Modesto, K., San Martin, J., Hellawell, J., & Ballantyne, C. M. (2024) · JAMA Cardiology

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 172

Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: rationale and design of the STRENGTH trial

Nicholls, S. J., Lincoff, A. M., Bash, D., Ballantyne, C. M., Barter, P. J., Davidson, M. H., Kastelein, J. J. P., Koenig, W., McGuire, D. K., Mozaffarian, D., et al. (2018) · Clinical Cardiology

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 167

Midlife systemic inflammatory markers are associated with late-life brain volume: The ARIC study

Walker, K. A., Hoogeveen, R. C., Folsom, A. R., Ballantyne, C. M., Knopman, D. S., Windham, B. G., Jack, C. R., & Gottesman, R. F. (2017) · Neurology

Dementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

Cited by 150

Proteomics analysis of plasma from middle-aged adults identifies protein markers of dementia risk in later life

Walker, K. A., Chen, J., Shi, L., Yang, Y., Fornage, M., Zhou, L., Schlosser, P., Surapaneni, A., Grams, M. E., Duggan, M. R., et al. (2023) · Science Translational Medicine

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 148

Biomarker-based risk prediction of incident heart failure in pre-diabetes and diabetes

Pandey, A., Vaduganathan, M., Patel, K. V., Ayers, C., Ballantyne, C. M., Kosiborod, M. N., Carnethon, M., DeFilippi, C., McGuire, D. K., Khan, S. S., et al. (2021) · JACC: Heart Failure

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 144

Icosapent Ethyl, a Pure Ethyl Ester of Eicosapentaenoic Acid: Effects on Circulating Markers of Inflammation from the MARINE and ANCHOR Studies

Bays, H. E., Ballantyne, C. M., Braeckman, R. A., Stirtan, W. G., & Soni, P. N. (2013) · American Journal of Cardiovascular Drugs

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 141

Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial

Rosenson, R. S., Gaudet, D., Ballantyne, C. M., Baum, S. J., Bergeron, J., Kershaw, E. E., Moriarty, P. M., Rubba, P., Whitcomb, D. C., Banerjee, P., et al. (2023) · Nature Medicine

Lipid metabolism and disordersPancreatitis Pathology and Treatment

Cited by 140

Utilization Rates of SGLT2 Inhibitors and GLP-1 Receptor Agonists and Their Facility-Level Variation Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes: Insights From the Department of Veterans Affairs

Mahtta, D., Ramsey, D. J., Lee, M. T., Chen, L., Al Rifai, M., Akeroyd, J. M., Vaughan, E. M., Matheny, M. E., Santo, K. R. D. E., Navaneethan, S. D., et al. (2022) · Diabetes Care

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 137

REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States

Bhatt, D. L., Miller, M., Brinton, E. A., Jacobson, T. A., Steg, P. G., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2020) · Circulation

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 136

A Prospective Study of Plasma Ferritin Level and Incident Diabetes: The Atherosclerosis Risk in Communities (ARIC) Study

Jehn, M. L., Guallar, E., Clark, J. M., Couper, D., Duncan, B. B., Ballantyne, C. M., Hoogeveen, R. C., Harris, Z. L., & Pankow, J. S. (2007) · American Journal of Epidemiology

Iron Metabolism and DisordersDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 136

Eotaxin and Obesity

Vasudevan, A. R., Wu, H., Xydakis, A. M., Jones, P. H., Smith, E. O., Sweeney, J. F., Corry, D. B., & Ballantyne, C. M. (2006) · The Journal of Clinical Endocrinology & Metabolism

Adipokines, Inflammation, and Metabolic DiseasesCardiovascular Disease and Adiposity

Cited by 132

Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy

Ridker, P. M., Rifai, N., MacFadyen, J., Glynn, R. J., Jiao, L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Tardif, J.-C., et al. (2022) · Circulation

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 131

Use of Guideline-Recommended Risk Reduction Strategies Among Patients With Diabetes and Atherosclerotic Cardiovascular Disease: Insights From Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management (GOULD)

Arnold, S. V., de Lemos, J. A., Rosenson, R. S., Ballantyne, C. M., Liu, Y., Mues, K. E., Alam, S., Elliott-Davey, M., Bhatt, D. L., Cannon, C. P., et al. (2019) · Circulation

Diabetes, Cardiovascular Risks, and LipoproteinsClinical practice guidelines implementation

Cited by 130

Prognostic value of cardiovascular biomarkers in the population

Neumann, J. T., Twerenbold, R., Weimann, J., Ballantyne, C. M., Benjamin, E. J., Costanzo, S., de Lemos, J. A., deFilippi, C. R., Di Castelnuovo, A., Donfrancesco, C., et al. (2024) · JAMA

Lipoproteins and Cardiovascular HealthCardiovascular Health and Risk Factors

Cited by 125

Effects of diet-induced obesity on inflammation and remodeling after myocardial infarction

Thakker, G. D., Frangogiannis, N. G., Bujak, M., Zymek, P., Gaubatz, J. W., Reddy, A. K., Taffet, G., Michael, L. H., Entman, M. L., & Ballantyne, C. M. (2006) · American Journal of Physiology-Heart and Circulatory Physiology

Cardiac Fibrosis and RemodelingCardiovascular Function and Risk Factors

Cited by 121

Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase

Bilen, O., & Ballantyne, C. M. (2016) · Current Atherosclerosis Reports

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 119

Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: An Expert Clinical Consensus from the National Lipid Association

Soffer, D. E., Marston, N. A., Maki, K. C., Jacobson, T. A., Bittner, V. A., Peña, J. M., Thanassoulis, G., Martin, S. S., Kirkpatrick, C. F., Virani, S. S., et al. (2024) · Journal of Clinical Lipidology

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 115

Follow-up lipid tests and physician visits are associated with improved adherence to statin therapy

Benner, J. S., Tierce, J. C., Ballantyne, C. M., Prasad, C., Bullano, M. F., Willey, V. J., Erbey, J., & Sugano, D. S. (2004) · PharmacoEconomics

Medication Adherence and ComplianceLipoproteins and Cardiovascular Health

Cited by 115